uniQure (NASDAQ:QURE) Upgraded at Wells Fargo & Company

uniQure (NASDAQ:QURE) was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating in a report issued on Monday,Benzinga reports. The firm presently has a $60.00 price target on the biotechnology company’s stock, up from their prior price target of $15.00. Wells Fargo & Company‘s target price would indicate a potential upside of 320.46% from the stock’s current price.

Several other research firms have also issued reports on QURE. Mizuho reissued a “neutral” rating and set a $12.00 target price (down from $33.00) on shares of uniQure in a research note on Tuesday, March 3rd. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. William Blair reaffirmed a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. TD Cowen reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Finally, The Goldman Sachs Group dropped their price objective on uniQure from $37.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, March 3rd. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, uniQure has an average rating of “Hold” and an average target price of $38.08.

uniQure Price Performance

Shares of NASDAQ QURE opened at $14.27 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The stock has a market capitalization of $892.30 million, a price-to-earnings ratio of -4.14 and a beta of 0.73. The firm’s 50 day simple moving average is $22.04 and its 200-day simple moving average is $29.63. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. Analysts expect that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling

In other news, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the sale, the chief financial officer directly owned 226,581 shares of the company’s stock, valued at $2,052,823.86. The trade was a 5.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the sale, the insider owned 138,483 shares of the company’s stock, valued at $1,254,655.98. The trade was a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 81,399 shares of company stock worth $1,527,645 in the last quarter. 4.79% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. acquired a new stake in shares of uniQure in the second quarter valued at about $29,217,000. State Street Corp boosted its position in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. grew its stake in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares in the last quarter. Avoro Capital Advisors LLC raised its holdings in uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after acquiring an additional 1,705,556 shares during the last quarter. Finally, MPM Bioimpact LLC purchased a new position in uniQure in the 4th quarter worth approximately $33,062,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.